Prelude Therapeutics Inc

Pharmaceutical Preparations

PRLD Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001678660 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$365.57M
79,803,485 shares Covers every share class this company has on file.
Insiders on file
2
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$17.33M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
4.74%
insider-held value divided by market capitalisation

What Prelude Therapeutics Inc reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$12.14M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$99.50M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
79
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Prelude Therapeutics Inc

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Prelude Therapeutics Inc.
Insider Reported role Shares Value Last action
Officers 1
Andrew Combs Other Executive 480,123 $2.62M P Open-market purchase Mar 25, 2025 position reported
Officers who also sit on the board 1
Krishna Vaddi CEO 2,693,625 $14.71M P Open-market purchase Mar 25, 2025 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Krishna Vaddi bought 675,000 Prelude Therapeutics Inc (PRLD) shares for $465,750 on Mar 25, 2025

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Krishna Vaddi bought 675,000 Prelude Therapeutics Inc (PRLD) shares for $465,750 on Mar 25, 2025
Date Insider Transaction Shares Price Value Filing
Mar 25, 2025 Krishna Vaddi P Open-market purchase 675,000 held after: 1,999,296 $0.69 $465,750 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Krishna Vaddi bought 675,000 Prelude Therapeutics Inc (PRLD) shares for $465,750 on Mar 25, 2025

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

Krishna Vaddi bought 675,000 Prelude Therapeutics Inc (PRLD) shares for $465,750 on Mar 25, 2025
Date Insider Transaction Shares Price Value Filing
Mar 25, 2025 Krishna Vaddi P Open-market purchase 675,000 held after: 1,999,296 $0.69 $465,750 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 16 rows we hold, 16 are open-market purchases (P) and 0 open-market sales — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Prelude Therapeutics Inc, newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Apr 21, 2026 David P Bonita P Open-market purchase 1,126,126 $4.44 $5.00M SEC filing ↗
Apr 21, 2026 David P Bonita P Open-market purchase 1,689,189 $4.44 $7.50M SEC filing ↗
Mar 25, 2025 Andrew Combs P Open-market purchase 100,000 $0.69 $69.0K SEC filing ↗
Mar 25, 2025 Krishna Vaddi P Open-market purchase 675,000 $0.69 $465.8K SEC filing ↗
Mar 21, 2025 Krishna Vaddi P Open-market purchase 15,000 $0.73 $11.0K SEC filing ↗
Mar 20, 2025 Krishna Vaddi P Open-market purchase 5,416 $0.73 $4.0K SEC filing ↗
Mar 17, 2025 Krishna Vaddi P Open-market purchase 9,106 $0.75 $6.8K SEC filing ↗
Mar 14, 2025 Krishna Vaddi P Open-market purchase 29,999 $0.75 $22.5K SEC filing ↗
Mar 13, 2025 Krishna Vaddi P Open-market purchase 50,000 $0.72 $36.0K SEC filing ↗
Mar 12, 2025 Krishna Vaddi P Open-market purchase 47,500 $0.71 $33.7K SEC filing ↗
Dec 31, 2024 Krishna Vaddi P Open-market purchase 5,000 $1.21 $6.1K SEC filing ↗
Dec 30, 2024 Krishna Vaddi P Open-market purchase 10,000 $1.20 $12.0K SEC filing ↗
Dec 23, 2024 Andrew Combs P Open-market purchase 60,000 $1.37 $82.2K SEC filing ↗
Dec 20, 2024 Andrew Combs P Open-market purchase 3,075 $1.15 $3.5K SEC filing ↗
Dec 19, 2024 Krishna Vaddi P Open-market purchase 6,888 $0.89 $6.1K SEC filing ↗
Dec 18, 2024 Krishna Vaddi P Open-market purchase 100,000 $0.93 $93.0K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 4 filers hold a position

Who owns Prelude Therapeutics Inc

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Filers holding a position in Prelude Therapeutics Inc

Funds, trusts and companies that disclose an ownership position in Prelude Therapeutics Inc.
Owner Reported role Shares Filed
667, L.P. Director,Other,TenPercentOwner —
Baker Bros. Advisors (GP) LLC Director,Other,TenPercentOwner —
BAKER BROS. ADVISORS LP Director,Other,TenPercentOwner —
Baker Brothers Life Sciences LP Director,Other,TenPercentOwner —

See the full ownership map — every entity that files as an owner of a US public company.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Prelude Therapeutics Inc’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Prelude Therapeutics Inc’s own SEC filings multiplied by the closing price we hold for the same stock.